MedTrace Logo

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

NCT07251998 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2025-12-31

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

Interventions

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet for 12 weeks

OTHER

ICP-332 Placebo Tablets

Placebo will be administered as tablet for 12 weeks

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuling Shi · Shanghai Dermatology Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-22
Primary Completion
2026-10-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07251998 on ClinicalTrials.gov